Trial Profile
ITI-007 (Lumateperone Tosylate) for Schizophrenia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2021
Price :
$35
*
At a glance
- Drugs Lumateperone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 02 Feb 2021 Status changed from suspended to discontinued as ITI-007 approved by FDA
- 21 Apr 2020 Status changed from recruiting to suspended.
- 01 Oct 2019 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.